Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review

References

• Available from: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases. Accessed October 20, 2020.
   Google Scholar
• Lin L, Lu LF, Cao W, et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg Microb Infect. 2020;9(1):727–732. doi:10.1080/22221751.2020.1746199
   PubMed Web of Science ®Google Scholar
• Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. doi:10.1183/13993003.00607-2020
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention [published online ahead of print, 2020 Feb 24]. JAMA. 2020;10.1001/jama.2020.2648. doi:10.1001/jama.2020.2648
   Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo- EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. doi:10.1126/science.abb2507
   PubMed Web of Science ®Google Scholar
• Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3(1):237–261. doi:10.1146/annurev-virology-110615-042301
   PubMed Web of Science ®Google Scholar
• Gui M, Song W, Zhou H, et al. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res. 2017;27(1):119–129. doi:10.1038/cr.2016.152
   PubMed Web of Science ®Google Scholar
• Walls AC, Xiong X, Park YJ, et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell. 2019;176(5):1026–39.e15. doi:10.1016/j.cell.2018.12.028
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Available from: https://coronavirus.jhu.edu/data/racial-data-transparency. Accessed October 20, 2020.
   Google Scholar
• Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-19. Accessed October 20, 2020.
   Google Scholar
• Mackenzie JS, Smith DW. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t. Microbiol Aust. 2020;MA20013. doi:10.1071/MA20013
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-7
   PubMed Web of Science ®Google Scholar
• Cascella M, Rajnik M, Cuomo A, et al. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
   Google Scholar
• Lam TT, Shum MH, Zhu HC, et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. 2020;583(7815):282–285. doi:10.1038/s41586-020-2169-0
   PubMed Web of Science ®Google Scholar
• Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12(4):372. doi:10.3390/v12040372
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Bushmaker T, Morris DH. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–1567. doi:10.1056/NEJMc2004973
   PubMed Web of Science ®Google Scholar
• Salehi S, Abedi A, Balakrishnan S, et al. Coronavirus disease 2019 (COVID- 19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol. 2020:1–7. doi:10.2214/AJR.20.23034.
   Web of Science ®Google Scholar
• Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631–637. doi:10.1002/path.1570
   PubMed Web of Science ®Google Scholar
• Li H, Liu SM, Yu XH, et al. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrobial Agents. 2020;55(5):105951. doi:10.1016/j.ijantimicag.2020.1
   PubMed Web of Science ®Google Scholar
• Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Accessed October 20, 2020.
   Google Scholar
• Thevarajan I, Buising KL, Cowie BC. Clinical presentation and management of COVID-19. Med J Aust. 2020;213(3):134–139. doi:10.5694/mja2.50698
   PubMed Web of Science ®Google Scholar
• Ho JC, Chan KN, Hu WH, et al. The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia. Am J Respir Crit Care Med. 2001;163:983–988. doi:10.1164/ajrccm.163.4.9909121
   PubMed Web of Science ®Google Scholar
• Epidemiology Working Group for NCIP Epidemic Response. Chinese center for disease control and prevention. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003.
   PubMedGoogle Scholar
• Di Stadio A, Ricci G, Greco A, et al. Mortality rate and gender differences in COVID-19 patients dying in Italy: a comparison with other countries. Eur Rev Med Pharmacol Sci. 2020;24(8):4066–4067. doi:10.26355/eurrev-202004-20980
   PubMed Web of Science ®Google Scholar
• Jin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. doi:10.3389/fpubh.2020.00152
   PubMed Web of Science ®Google Scholar
• Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–815. doi:10.1016/S0140-6736(20)30360-3
   PubMed Web of Science ®Google Scholar
• Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr. 2020;10(6):537–540. doi:10.1542/hpeds.2020-0123
   PubMedGoogle Scholar
• Esper FED, Shapiro C, Weibel D, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis. 2005;191(4):499–502. doi:10.1086/428291
   PubMed Web of Science ®Google Scholar
• Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/index.html. Accessed October 20, 2020.
   Google Scholar
• Curtis N, Sparrow A, Ghebreyesus TA, et al. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395(10236):1545–1546. doi:10.1016/S0140-6736(20)31025-4
   PubMed Web of Science ®Google Scholar
• Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet. 2020;395(10224):e39. doi:10.1016/S0140-6736(20)30313-5
   PubMed Web of Science ®Google Scholar
• Xia J, Tong J, Liu M, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020;92(6):589–594. doi:10.1002/jmv.25725
   PubMed Web of Science ®Google Scholar
• Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–582. doi:10.7326/M20-0504
   PubMed Web of Science ®Google Scholar
• Novel coronavirus (2019-ncov) situation report-7. World Health Organization (WHO). 2020 January 27. Accessed October 20, 2020.
   Google Scholar
• China’s national health commission news conference on coronavirus. Al Jazeera. 2020 January 26. Accessed October 20, 2020.
   Google Scholar
• Symptoms of novel coronavirus (2019-nCoV)-CDC. Accessed October 20, 2020.
   Google Scholar
• Varia M, Wilson S, Sarwal S, et al. Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. CMAJ. 2003;169:285–292.
   PubMed Web of Science ®Google Scholar
• Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–971. doi:10.1056/NEJMc2001468
   PubMed Web of Science ®Google Scholar
• Quilty BJ, Clifford S, Flasche S, et al. Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV). Euro Surveill. 2020;25(5):2000080. doi:10.2807/1560-7917.ES.2020.25.5.2000080
   PubMedGoogle Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032
   PubMed Web of Science ®Google Scholar
• Coronavirus incubation could be as long as 27 days, Chinese provincial government says. Reuters. 2020 Feb 22. Accessed October 20, 2020.
   Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X
   PubMed Web of Science ®Google Scholar
• Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282–289. doi:10.1002/path.1440
   PubMed Web of Science ®Google Scholar
• Deshmukh V, Motwani R, Kumar A, et al. Histopathological observations in COVID-19: a systematic review. J Clin Pathol. 2020:jclinpath-2020-206995. doi:10.1136/jclinpath-2020-206995.
   PubMed Web of Science ®Google Scholar
• Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020;295(1):202–207. doi:10.1148/radiol.2020200230
   PubMed Web of Science ®Google Scholar
• Li W, Cui H, Li K, et al. Chest computed tomography in children with COVID-19 respiratory infection. Pediatr Radiol. 2020;50(6):796–799. doi:10.1007/s00247-020-04656-7
   PubMed Web of Science ®Google Scholar
• Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045. doi:10.2807/1560-7917
   PubMedGoogle Scholar
• Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi:10.1016/S0140-6736(20)30154-9
   PubMed Web of Science ®Google Scholar
• Carver C, Jones N. Comparative accuracy of oropharyngeal and nasopharyngeal swabs for diagnosis of COVID-19. Oxford COVID-19 evidence service team centre for evidence-based medicine; 2020. Available from: https://www.cebm.net/covid-19/comparative-accuracy-of-oropharyngeal-and-nasopharyngeal-swabs-for-diagnosis-of-covid-19/. Accessed October 20, 2020.
   Google Scholar
• Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843–1844. doi:10.1001/jama.2020.3786
   PubMed Web of Science ®Google Scholar
• To KK, Tsang OT, Yip CC, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020;71(15):841–843. doi:10.1093/cid/ciaa149
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Kahn R, Mina MJ. Antibody testing will enhance the power and accuracy of COVID-19 prevention trials. Nat Med. 2020;26(6):818–819. doi:10.1038/s41591-020-0887-3
   PubMed Web of Science ®Google Scholar
• Zhang F, Abudayyeh OO, Gootenberg JS. A Protocol for Detection of COVID-19 Using CRISPR Diagnostics. Cambridge, MA: Broad Institute, MIT; 2020.
   Google Scholar
• Bosch BJ, van der Zee R, de Haan CA, et al. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801–8811. doi:10.1128/jvi.77.16.8801-8811.2003
   PubMed Web of Science ®Google Scholar
• Yuan Y, Cao D, Zhang Y, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun. 2017;8(1):15092. doi:10.1038/ncomms15092
   PubMedGoogle Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. doi:10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Braciale TJ, Hahn YS. Immunity to viruses. Immunol Rev. 2013;255(1):5–12. doi:10.1111/imr.12109
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. doi:10.1038/nature02145
   PubMed Web of Science ®Google Scholar
• Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185–192. doi:10.1007/s11684-020-0754-0
   PubMed Web of Science ®Google Scholar
• Sungnak W, Huang N, Bécavin C, et al. HCA lung biological network. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687. doi:10.1038/s41591-020-0868-6
   PubMed Web of Science ®Google Scholar
• Das SK. The pathophysiology, diagnosis and treatment of corona virus disease 2019 (COVID-19). Indian J Clin Biochem. 2020;35(4):1–12. doi:10.1007/s12291-020-00919-0
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–793. doi:10.1001/jama.2020.12839
   PubMed Web of Science ®Google Scholar
• Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382(25):2431–2440. doi:10.1056/NEJMoa2006923
   PubMed Web of Science ®Google Scholar
• Fosbøl EL, Butt JH, Østergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324(2):168–77. doi:10.1001/jama.2020.11301
   PubMed Web of Science ®Google Scholar
• Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. doi:10.3389/fimmu.2020.01446
   PubMed Web of Science ®Google Scholar
• Shimizu M. Clinical features of cytokine storm syndrome. In: Cron R, Behrens E, editors. Cytokine Storm Syndrome. Cham: Springer; 2019:31–42. doi:10.1007/978-3-030-22094-5_3
   Google Scholar
• Fletcher-Sandersjöö A, Bellander BM. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review [published online ahead of print, 2020 Jun 18]. Thromb Res. 2020;194:36–41. doi:10.1016/j.thromres.2020.06.027
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013
   PubMed Web of Science ®Google Scholar
• Lai C, Shih T, Ko W, Tang H, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi:10.1016/j.ijantimicag.2020.105924
   PubMed Web of Science ®Google Scholar
• Ishikawa T. Clinical preparedness for cytokine storm induced by the highly pathogenic H5N1 influenza virus. J Pharmacogenom Pharmacoproteomics. 2012;3(6):1000e131. doi:10.4172/2153-0645.1000e131
   Google Scholar
• Task Force BM, BASE Medicine Task Force. COVID-19: facts and recommendations from A to Z. Sci Insight. 2020;33(1):138–158. doi:10.15354/si.20.re061
   Google Scholar
• Yousefifard M, Zali A, Mohamed Ali K, et al. Antiviral therapy in management of COVID-19: a systematic review on current evidence. Arch Acad Emerg Med. 2020;8(1):e45.
   PubMedGoogle Scholar
• Scagnolari C, Vicenzi E, Bellomi F, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther. 2004;9:1003–1011.
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343. doi:10.1371/journal.pmed.0030343
   PubMed Web of Science ®Google Scholar
• Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–1913. doi:10.1093/infdis/jiv392
   PubMed Web of Science ®Google Scholar
• Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69–75. doi:10.1016/j.jcv.2004.03.003
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003;290(24):3222–3228. doi:10.1001/jama.290.24.3222
   PubMed Web of Science ®Google Scholar
• Jr SB, Mossel EC, Peters CJ, et al. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004;329(1):11–17. doi:10.1016/j.virol.2004.08.011
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b treatment for COVID-19. Front Immunol. 2020;11:1061. doi:10.3389/fimmu.2020.01061
   PubMed Web of Science ®Google Scholar
• Available from: https://www.covid19treatmentguidelines.nih.gov/immune-basedtherapy/immunomodulators/interferons/. Accessed October 20, 2020.
   Google Scholar
• Adaptive COVID-19 treatment trial 3 (ACTT-3). Available from: https://clinicaltrials.gov/ct2/show/NCT04492475?term=NCT04492475&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Pegylated interferon lambda treatment for COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04343976?term=NCT04343976&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• An investigation into beneficial effects of interferon beta 1a, compared to interferon beta 1b and the base therapeutic regiment in moderate to severe COVID-19: a randomized clinical trial (COVIFERON). Available from: https://clinicaltrials.gov/ct2/show/NCT04343768?term=NCT04343768&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
   Google Scholar
• Wenzel RP, Edmond MB. Managing SARS amidst uncertainty. N Engl J Med. 2003;348(20):1947–1948. doi:10.1056/NEJMp030072
   PubMed Web of Science ®Google Scholar
• Morgenstern B, Michaelis M, Baer PC, et al. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326(4):905–908. doi:10.1016/j.bbrc.2004.11.128
   PubMed Web of Science ®Google Scholar
• Khalili JS, Zhu H, Mak NSA, et al. Novel coronavirus treatment with ribavirin: groundwork for evaluation concerning COVID-19. J Med Virol. 2020;92(7):740–746. doi:10.1002/jmv.25798
   PubMed Web of Science ®Google Scholar
• de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci. 2020;117(12):6771–6776. doi:10.1073/pnas.1922083117
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi:10.1056/NEJMoa2001191
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - final report [published online ahead of print, 2020 Oct 8]. N Engl J Med. 2020:NEJMoa2007764. doi:10.1056/NEJMoa2007764.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-9
   PubMed Web of Science ®Google Scholar
• Adaptive COVID-19 treatment trial (ACTT). Available from: https://clinicaltrials.gov/ct2/show/NCT04280705?term=NCT04280705&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04292899?term=NCT04292899&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment. Available from: https://clinicaltrials.gov/ct2/show/NCT04292730?term=NCT04292730&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• A study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized participants with severe COVID-19 pneumonia (REMDACTA). Available from: https://clinicaltrials.gov/ct2/show/NCT04409262?term=NCT04409262&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl). 2015;7:95–104. doi:10.2147/HIV.S79956
   PubMedGoogle Scholar
• Kim UJ, Won EJ, Kee SJ, et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455–459. doi:10.3851/IMP3002
   PubMed Web of Science ®Google Scholar
• Lin S, Shen R, Guo X. Molecular modeling evaluation of the binding abilities of ritonavir and lopinavir to Wuhan pneumonia coronavirus proteases. bioRxiv. 2020. doi:10.1101/2020.01.31.929695
   Google Scholar
• Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004;318(3):719–725. doi:10.1016/j.bbrc.2004.04.083
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Matsuyama S, Hoshino T, et al. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. bioRxiv. 2020. doi:10.1101/2020.04.06.026476
   Google Scholar
• Randomised evaluation of COVID-19 therapy (recovery). Available from: https://clinicaltrials.gov/ct2/show/NCT04381936?term=NCT04381936&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Khamitov RA, Loginova S, Shchukina VN, et al. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol. 2008;53:9–13.
   PubMedGoogle Scholar
• Huang L, Zhang L, Liu Y, et al. Arbidol for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2017;2017(2):CD011489. doi:10.1002/14651858.CD011489.pub2
   Google Scholar
• Zhang J, Zhou L, Yang Y, et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020;8(3):e11–e12. doi:10.1016/S2213-2600(20)30071-0
   PubMed Web of Science ®Google Scholar
• Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21–e23. doi:10.1016/j.jinf.2020.03.060
   PubMed Web of Science ®Google Scholar
• Clinical study of arbidol hydrochloride tablets in the treatment of pneumonia caused by novel coronavirus. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04260594?term=arbidol&cond=covid+19&draw=2&rank=3. Accessed October 20, 2020.
   Google Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–727. doi:10.1016/s1473-3099(03)00806-5
   PubMed Web of Science ®Google Scholar
• Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300–302. doi:10.1038/cr.2012.165
   PubMed Web of Science ®Google Scholar
• Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–283. doi:10.1016/j.jcrc.2020.03.005
   PubMed Web of Science ®Google Scholar
• Dexamethasone treatment for severe acute respiratory distress syndrome induced by COVID-19 (DHYSCO). Available from: https://clinicaltrials.gov/ct2/show/NCT04347980?term=NCT04347980&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Randomized clinical trial for the prevention of sars-cov-2 infection (COVID-19) in healthcare personnel (EPICOS). Available from: https://clinicaltrials.gov/ct2/show/NCT04334928?term=NCT04334928&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Available from: http://chemocare.com/chemotherapy/drug-info/dexamethasone.aspx. Accessed October 20, 2020.
   Google Scholar
• Available from: https://www.nice.org.uk/guidance/ng159/resources/covid19-prescribing-briefing-corticosteroids-pdf-8839913581. Accessed October 20, 2020.
   Google Scholar
• Mahase E. Covid-19: hydrocortisone can be used as alternative to dexamethasone, review finds. BMJ. 2020;370:m3472. doi:10.1136/bmj.m3472
   PubMedGoogle Scholar
• Randomized clinical trial of intranasal dexamethasone as an adjuvant in patients with COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04513184?term=NCT04513184&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Higher vs. lower doses of dexamethasone for COVID-19 and severe hypoxia (COVIDSTEROID2). Available from: https://clinicaltrials.gov/ct2/show/NCT04509973?term=NCT04509973&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Available from: https://www.popsci.com/story/health/convalescent-plasma-covid-19-coronavirus/. Accessed October 20, 2020.
   Google Scholar
• Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion. 2012;52(Suppl 1):65S–79S. doi:10.1111/j.1537-2995.2012.03663.x
   PubMedGoogle Scholar
• Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450–1451. doi:10.1056/NEJMc070359
   PubMed Web of Science ®Google Scholar
• van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42. doi:10.1056/NEJMoa1511812
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. doi:10.1007/s10096-004-1271-9
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490. doi:10.1073/pnas.2004168117:202004168
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(2251):1–6. doi:10.1038/s41467-020-16256-y
   PubMedGoogle Scholar
• Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study [published correction appears in lancet rheumatol. 2020;2(10):e591]. Lancet Rheumatol. 2020;2(8):e474–e484. doi:10.1016/S2665-9913(20)30173-9
   PubMedGoogle Scholar
• Available from: https://www.versusarthritis.org/about-arthritis/treatments/drugs/tocilizumab/. Accessed October 20, 2020.
   Google Scholar
• Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972–1988. doi:10.1080/21645515.2017.1316909
   PubMed Web of Science ®Google Scholar
• Lan SH, Lai CC, Huang HT, et al. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56(3):106103. doi:10.1016/j.ijantimicag.2020.106103
   PubMed Web of Science ®Google Scholar
• Available from: https://www.drugs.com/kineret.html. Accessed October 20, 2020.
   Google Scholar
• Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–e400. doi:10.1016/S2665-9913(20)30164-8
   PubMedGoogle Scholar
• Favipiravir combined with tocilizumab in the treatment of corona virus disease; 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT04310228. Accessed October 20, 2020.
   Google Scholar
• A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA). Available from: https://clinicaltrials.gov/ct2/show/NCT04320615. Accessed October 20, 2020.
   Google Scholar
• Tocilizumab in COVID-19 pneumonia (TOCIVID-19) (TOCIVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04317092. Accessed October 20, 2020.
   Google Scholar
• Tocilizumab for SARS-CoV2 (COVID-19) severe pneumonitis. Available from: https://clinicaltrials.gov/ct2/show/NCT04315480. Accessed October 20, 2020.
   Google Scholar
• Anti-il6 treatment of serious COVID-19 disease with threatening respiratory failure (TOCIVID). Available from: https://clinicaltrials.gov/ct2/show/NCT04322773. Accessed October 20, 2020.
   Google Scholar
• CORIMUNO-19-tocilizumab trial-TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). Available from: https://clinicaltrials.gov/ct2/show/NCT04331808. Accessed October 20, 2020.
   Google Scholar
• Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia. Available from: https://pipelinereview.com/index.php/2020042874458/Antibodies/Tocilizumab-improves-significantly-clinical-outcomes-of-patients-with-moderate-or-severe-COVID-19-pneumonia.html. Accessed October 20, 2020.
   Google Scholar
• Press release. First randomized study favorable to tocilizumab in Covid-19, in France. Available from: https://www.apmnews.com/depeche/0/350489/premiere-etude-randomisee-favorable-au-tocilizumab-dans-le-covid-19%2C-en-france. Accessed October 20, 2020.
   Google Scholar
• Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04315298. Accessed October 20, 2020.
   Google Scholar
• Erman M, Joseph S. Regeneron, Sanofi arthritis drug may only help critical coronavirus patients: study. Available from: https://www.reuters.com/article/us-health-coronavirus-regeneron-pharms/regeneron-sanofi-to-treat-only-critical-covid-19-patients-with-arthritis-drug-idUSKCN2291OD. Accessed October 20, 2020.
   Google Scholar
• Cohort multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients—sarilumab trial—CORIMUNO-19—SARI (CORIMUNO-SARI). Available from: https://clinicaltrials.gov/ct2/show/study/NCT04324073. Accessed October 20, 2020.
   Google Scholar
• Efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID-19 pneumonia. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04329650?cond=siltuximab+covid+19&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Clinical trial of the use of anakinra in cytokine storm syndrome secondary to Covid-19 (ANA-COVID-GEAS) (ANA-COVID-GEAS). Available from: https://clinicaltrials.gov/ct2/show/NCT04443881?term=NCT04443881&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Available from: https://www.recoverytrial.net/news/recovery-covid-19-phase-3-trial-to-evaluate-regeneron2019s-regn-cov2-investigational-antibody-cocktail-in-the-uk. Accessed October 20, 2020.
   Google Scholar
• Available from: https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and. Accessed October 20, 2020.
   Google Scholar
• Lo Caputo S, Corso G, Clerici M, et al. Baricitinib: a chance to treat COVID-19? [published online ahead of print, 2020 May 21]. J Med Virol. 2020:10.1002/jmv.26033. doi:10.1002/jmv.26033.
   PubMedGoogle Scholar
• Recombinant bacterial ACE2 receptors -like enzyme of B38-CAP could be promising COVID-19 infection- and lung injury preventing drug better than recombinant human ACE2 (bacterial ACE2). Available from: https://clinicaltrials.gov/ct2/show/NCT04375046?term=NCT04375046&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Combination of recombinant bacterial ACE2 receptors -like enzyme of B38-CAP and isotretinoin could be promising COVID-19 infection- and lung injury preventing drug better than recombinant human ACE2. Available from: https://clinicaltrials.gov/ct2/show/NCT04382950?term=NCT04382950&draw=2&rank=1. Accessed November 23, 2020.
   Google Scholar
• Evaluation of safety and efficiency of method of exosome inhalation in SARS-CoV-2 associated pneumonia. (COVID-19EXO). Available from: https://clinicaltrials.gov/ct2/show/NCT04491240?term=NCT04491240&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• COVID-19 specific T cell derived exosomes (CSTC-Exo). Available from: https://clinicaltrials.gov/ct2/show/NCT04389385?term=NCT04389385&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Zofin (organicell flow) for patients with COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04384445?term=NCT04384445&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus pneumonia. Available from: https://clinicaltrials.gov/ct2/show/NCT04276987?term=NCT04276987&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Administration of allogenic UC-MSCs as adjuvant therapy for critically-ill COVID-19 patients. Available from: https://clinicaltrials.gov/ct2/show/NCT04457609?term=NCT04457609&draw=1&rank=1. Accessed October 20, 2020.
   Google Scholar
• Renin-angiotensin system inhibitors and COVID-19 (SARS-RAS). Available from: https://clinicaltrials.gov/ct2/show/NCT04331574?term=NCT04331574&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• ACE inhibitors or ARBs discontinuation in context of SARS-CoV-2 pandemic (ACORES-2). Available from: https://clinicaltrials.gov/ct2/show/NCT04329195?term=NCT04329195&draw=1&rank=1. Accessed October 20, 2020.
   Google Scholar
• Stopping ACE-inhibitors in COVID-19 (ACEI-COVID). Available from: https://clinicaltrials.gov/ct2/show/NCT04353596?term=NCT04353596&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• TCM differentiation and treatment protocol of COVID-19 (TDATPOC). Available from: https://clinicaltrials.gov/ct2/show/NCT04306497?term=NCT04306497&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Treatment and prevention of traditional Chinese medicines (TCMs) on COVID-19 infection. Available from: https://clinicaltrials.gov/ct2/show/NCT04251871?term=NCT04251871&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Pharmacologic ascorbic acid as an activator of lymphocyte signaling for COVID-19 treatment. Available from: https://clinicaltrials.gov/ct2/show/NCT04363216?term=NCT04363216&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Use of ascorbic acid in patients with COVID 19. Available from: https://clinicaltrials.gov/ct2/show/NCT04323514?term=NCT04323514&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Vitamin D status and immune-inflammatory status in different UK populations with COVID-19 infection. Available from: https://clinicaltrials.gov/ct2/show/NCT04519034?term=NCT04519034&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Anti-inflammatory/antioxidant oral nutrition supplementation in COVID-19 (ONSCOVID19). Available from: https://clinicaltrials.gov/ct2/show/NCT04323228?term=NCT04323228&draw=2&rank=1.Accessed October 20, 2020.
   Google Scholar
• A phase II, controlled clinical study designed to evaluate the effect of artemiC in patients diagnosed with COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04382040?term=NCT04382040&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Honey & nigella sativa trial against COVID-19 (HNS-COVID-PK). Available from: https://clinicaltrials.gov/ct2/show/NCT04347382?term=NCT04347382&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Efficacy of natural honey treatment in patients with novel coronavirus. Available from: https://clinicaltrials.gov/ct2/show/NCT04323345?term=NCT04323345&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• The role of resistant starch in COVID-19 infection. Available from: https://clinicaltrials.gov/ct2/show/NCT04342689?term=NCT04342689&draw=2&rank=1. Accessed October 20, 2020.
   Google Scholar
• Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–1474. doi:10.1161/CIRCRESAHA.120.317015
   PubMed Web of Science ®Google Scholar
• Hassanpour M, Rezaie J, Nouri M, et al. The role of extracellular vesicles in COVID-19 virus infection [published online ahead of print, 2020 Jun 13]. Infect Genet Evol. 2020;85:104422. doi:10.1016/j.meegid.2020.104422
   PubMed Web of Science ®Google Scholar
• Li X, Corbett AL, Taatizadeh E, et al. Challenges and opportunities in exosome research-perspectives from biology, engineering, and cancer therapy. APL Bioeng. 2019;3(1):011503. doi:10.1063/1.5087122
   PubMed Web of Science ®Google Scholar
• Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;35(3):266. doi:10.1007/s12250-020-00207-4
   PubMed Web of Science ®Google Scholar
• Zhong J, Tang J, Ye C, et al. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):e428–e436. doi:10.1016/S2665-9913(20)30120-X
   PubMedGoogle Scholar
• Barochiner J, Martínez R. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis [published online ahead of print, 2020 Aug 7]. J Clin Pharm Ther. 2020;10.1111/jcpt.13246. doi:10.1111/jcpt.13246
   PubMed Web of Science ®Google Scholar
• Chen H, Du Q. Potential natural compounds for preventing 2019-nCoV infection. Preprints. 2020;2020010358. doi:10.20944/preprints202001.0358.v3
   Google Scholar
• Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment [published correction appears in pharmacol res. 2020 Mar 25;:104768]. Pharmacol Res. 2020;155:104743. doi:10.1016/j.phrs.2020.104743
   PubMed Web of Science ®Google Scholar
• Wang Y, Zeng X, Zhao Y, et al. The pros and cons of traditional Chinese medicines in the treatment of COVID-19. Pharmacol Res. 2020;157:104873. doi:10.1016/j.phrs.2020.104873
   PubMed Web of Science ®Google Scholar
• Gray PE, Belessis Y. The use of traditional Chinese medicines to treat SARS-CoV-2 may cause more harm than good. Pharmacol Res. 2020;156:104776. doi:10.1016/j.phrs.2020.104776
   PubMed Web of Science ®Google Scholar
• Yoshihara D, Fujiwara N, Suzuki K. Antioxidants: benefits and risks for long-term health. Maturitas. 2010;67(2):103–107. doi:10.1016/j.maturitas.2010.05.001
   PubMed Web of Science ®Google Scholar
• Available from: https://www.webmd.com/drugs/2/drug-15583/antioxidant-vitamins-oral/details/list-sideeffects. Accessed October 20, 2020.
   Google Scholar
• Zahedipour F, Hosseini SA, Sathyapalan T, et al. Potential effects of curcumin in the treatment of COVID-19 infection [published online ahead of print, 2020 May 19]. Phytother Res. 2020:10.1002/ptr.6738. doi:10.1002/ptr.6738.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.nutraingredients-asia.com/Article/2020/04/20/Can-honey-omega-3-resistant-potato-starch-help-fight-COVID-19-Researchers-to-examine-via-clinical-trials. Accessed October 20, 2020.
   Google Scholar
• Rogero MM, Leão MC, Santana TM, et al. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. Free Radic Biol Med. 2020;156:190–199. doi:10.1016/j.freeradbiomed.2020.07.005
   PubMed Web of Science ®Google Scholar
• Available from: https://www.webmd.com/a-to-z-guides/manuka-honey-medicinal-uses#1. Accessed October 20, 2020.
   Google Scholar
• Available from: https://atlasbiomed.com/blog/potato-resistant-starch/. Accessed October 20, 2020.
   Google Scholar
• Hossain K, Hossain M, Moni A, et al. Prospects of honey in fighting against COVID-19: pharmacological insights and therapeutic promises. OSF Preprints. 2020. doi:10.31219/osf.io/w3hqu
   Google Scholar
• Heiskanen V, Hamblin MR. Photobiomodulation: lasers vs. light emitting diodes? Photochem Photobiol Sci. 2018;17(8):1003–1017. doi:10.1039/c8pp90049c
   PubMed Web of Science ®Google Scholar
• Solmaz H, Ulgen Y, Gulsoy M. Photobiomodulation of wound healing via visible and infrared laser irradiation. Lasers Med Sci. 2017;32(4):903–910. doi:10.1007/s10103-017-2191-0
   PubMed Web of Science ®Google Scholar
• Gavish L, Houreld NN. Therapeutic efficacy of home-use photobiomodulation devices: a systematic literature review. Photomed Laser Surg. 2019;37(1):4–16. doi:10.1089/photob.2018.4512
   Web of Science ®Google Scholar
• de Freitas LF, Hamblin MR. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE J Sel Top Quantum Electron. 2016;22(3):7000417. doi:10.1109/JSTQE.2016.2561201
   PubMed Web of Science ®Google Scholar
• Amaroli A, Agas D, Lus F, et al. The effects of photobiomodulation of 808 nm diode laser therapy at higher fluence on the in vitro osteogenic differentiation of bone marrow stromal cell. Front Physiol. 2018;9(123):1–11. doi:10.3389/fphys.2018.00123
   PubMedGoogle Scholar
• Amaroli A, Ferrando S, Hanna R, et al. The photobiomodulation effect of higher-fluence 808-nm laser therapy with a flat-top handpiece on the wound healing of the earthworm Dendrobaena veneta: a brief report. Lasers Med Sci. 2018;33:221–225. doi:10.1007/s10103-016-2132-3
   PubMed Web of Science ®Google Scholar
• Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337–361. doi:10.3934/biophy.2017.3.337
   PubMed Web of Science ®Google Scholar
• Hanna R, Dalvi S, Amaroli A, et al. Effects of photobiomodulation on bone defects grafted with bone substitutes: a systematic review of in vivo animal studies. J Biophotonics. 2020;e202000267:1–41. doi:10.1002/jbio.202000267
   Google Scholar
• Hanna R, Agas D, Benedicenti S, et al. A comparative study between the effectiveness of 980 nm photobiomodulation delivered by hand-piece with Gaussian vs. flat-top profiles on osteoblasts maturation. Front Endocrinol. 2019;10:92. doi:10.3389/fendo.2019.00092
   PubMed Web of Science ®Google Scholar
• Aimbire F, Albertine R, de Magalhães RG, et al. Effect of LLLT Ga-Al-As (685 nm) on LPS-induced inflammation of the airway and lung in the rat. Lasers Med Sci. 2005;20(1):11–20. doi:10.1007/s10103-005-0339-9
   PubMed Web of Science ®Google Scholar
• Aimbire F, Lopes-Martins RA, Albertini R, et al. Effect of low-level laser therapy on hemorrhagic lesions induced by immune complexes in rat lungs. Photomed Laser Surg. 2007;25(2):112–117. doi:10.1089/pho.2006.1041
   PubMed Web of Science ®Google Scholar
• Aimbire F, Ligeiro de Oliveira AP, Albertini R, et al. Low level laser therapy (LLLT) decreases pulmonary microvascular leakage, neutrophil influx and IL-1beta levels in airway and lung from rat subjected to LPS- induced inflammation. Inflammation. 2008;31(3):189–197. doi:10.1007/s10753-008-9064-4
   PubMed Web of Science ®Google Scholar
• Oliveira MC, Greiffo FR, Rigonato-Oliveira NC, et al. Low level laser therapy reduces acute lung inflammation in a model of pulmonary and extrapulmonary LPS-induced ARDS. J Photochem Photobiol B. 2014;134:57–63. doi:10.1016/j.jphotobiol.2014.03.021
   PubMed Web of Science ®Google Scholar
• Mokmeli S, Vetrici M. Low level laser therapy as a modality to attenuate cytokine storm at multiple levels, enhance recovery, and reduce the use of ventilators in COVID-19. Can J Respir Ther. 2020;56:1–7. doi:10.29390/cjrt-2020-015
   Google Scholar
• Mafra de Lima F, Villaverde AB, Salgado MA, et al. Low intensity laser therapy (LILT) in vivo acts on the neutrophils recruitment and chemokines/cytokines levels in a model of acute pulmonary inflammation induced by aerosol of lipopolysaccharide from Escherichia coli in rat. J Photochem Photobiol B. 2010;101:271–278. doi:10.1016/j.jphotobiol.2010.07.012
   PubMed Web of Science ®Google Scholar
• Brochetti A, Leal MP, Rodrigues R, et al. Photobiomodulation therapy improves both inflammatory and fibrotic parameters in experimental model of lung fibrosis in mice. Lasers Med Sci. 2017;32(8):1825–1834. doi:10.1007/s10103-017-2281-z
   PubMed Web of Science ®Google Scholar
• de Brito AA, da Silveira EC, Rigonato-Liveira NC, et al. Low-level laser therapy attenuates lung inflammation and airway remodeling in a murine model of idiopathic pulmonary fibrosis, relevance to cytokines secretion from lung structural cells. J Photochem Photobiol B. 2020;203:111731. doi:10.1016/j.jphotobiol.2019.111731
   PubMed Web of Science ®Google Scholar
• Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19), The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi:10.1016/j.ijantimicag.2020.105924
   PubMed Web of Science ®Google Scholar
• Miranda da Silva C, Peres Leal M, Brochetti RA, et al. Low level laser therapy reduces the development of lung inflammation induced by formaldehyde exposure. PLoS One. 2015;10(11):e0142816. doi:10.1371/journal.pone.0142816
   PubMed Web of Science ®Google Scholar
• da Cunha Moraes G, Vitoretti LB, de Brito AA, et al. Low-level laser therapy reduces lung inflammation in an experimental model of chronic obstructive pulmonary disease involving p2x7 receptor. Oxid Med Cell Longev. 2018;2018:6798238. doi:10.1155/2018/6798238
   PubMed Web of Science ®Google Scholar
• Enwemeka CS, Bumah VV, Masson-Meyers DS. Light as a potential treatment for pandemic coronavirus infections: a perspective. J Photochem Photobiol B. 2020;207:111891. doi:10.1016/j.jphotobiol.2020.111891
   PubMed Web of Science ®Google Scholar
• Yusupalieva MM, Savtchenko VM. The effectiveness of combined laser therapy for the treatment of the patients presenting with bronchial asthma and concomitant allergic rhinitis. Vopr Kurortol Fizioter Lech Fiz Kult. 2017;94(4):14–18. doi:10.17116/kurort201794414-18
   PubMedGoogle Scholar
• Askenova IZ, Burduli NM. Pathogenetic effects of low-intensity laser therapy for chronic obstructive pulmonary disease. Ter Arkh. 2015;88:32–35. doi:10.17116/terarkh201688332-35
   Web of Science ®Google Scholar
• Sigman SA, Mokmeli S, Monici M, et al. A 57-year-old african american man with severe COVID-19 pneumonia who responded to supportive photobiomodulation therapy (PBMT): first use of PBMT in COVID-19. Am J Case Rep. 2020;21:e926779. doi:10.12659/AJCR.926779
   PubMed Web of Science ®Google Scholar
• Sigman SA, Mokmeli S, Vetrici MA. Adjunct low level laser therapy (LLLT) in a morbidly obese patient with severe COVID-19 pneumonia: a case report. Can J Respir Ther. 2020;56:52–56. doi:10.29390/cjrt-2020-022
   PubMedGoogle Scholar
• Giannelli M, Bani D. Appropriate laser wavelengths for photodynamic therapy with methylene blue. Lasers Med Sci. 2018;33(8):1837–1838. doi:10.1007/s10103-018-2566-x
   PubMed Web of Science ®Google Scholar
• Dias LD, Bagnato VS. An update on clinical photodynamic therapy for fighting respiratory tract infections: a promising tool against COVID-19 and its co-infections. Laser Phys Lett. 2020;17(8):1–9. doi:10.1088/1612-202X/ab95a9
   Web of Science ®Google Scholar
• Wainright M, Crossley KB. Photosensitizing agents- circumventing resistance and breaking down biofilms: a review. Int Biodeter Biodegr. 2004;53(2):119–126. doi:10.1016/j.ibiod.2003.11.006
   Web of Science ®Google Scholar
• Hu XQ, Huang YY, Wang YG. Antimicrobial photodynamic therapy to control clinically relevant biofilm infections. Front Microbiol. 2019;9(1299):1–24. doi:10.3389/fmicb.2018.01299
   Google Scholar
• Wiehe A, O’Brien JM, Senge MO. Trends and targets in antiviral phototherapy. Photochem Photobiol Sci. 2019;18(11):2565–2612. doi:10.1039/c9pp00211a
   PubMed Web of Science ®Google Scholar
• Moan J, Berg K, Kvam E, et al. Intracellular localization of photosensitizers. Ciba Found Symp. 1989;146:95–107. doi:10.1002/9780470513842.ch7
   PubMedGoogle Scholar
• Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; coronavirus disease-19). Clin Exp Pediatr. 2020;63(4):119–124. doi:10.3345/cep.2020.00493
   PubMedGoogle Scholar
• Woelfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized cases of coronavirus disease 2019. medRxiv. 2020;03:05.20030502. doi:10.1101/2020.03.05.20030502
   Google Scholar
• Oh MD, Park WB, Choe PG, et al. Viral load kinetics of MERS coronavirus infection. N Engl J Med. 2016;375(13):1303–1305. doi:10.1056/NEJMc1511695
   PubMed Web of Science ®Google Scholar
• Blanco KC, Inada NM, Carbinatto FM, et al. Treatment of recurrent pharyngotonsillitis by photodynamic therapy. Photodiagnosis Photodyn Ther. 2017;18:138–139. doi:10.1016/j.pdpdt.2017.01.187
   PubMed Web of Science ®Google Scholar
• Sécher T, Alexie Mayor A, Heuzé-Vourc’h N. Inhalation of immuno-therapeutics/- prophylactics to fight respiratory tract infections: an appropriate drug at the right place! Front Immunol. 2019;10(2760):1–6. doi:10.3389/fimmu.2019.02760
   PubMedGoogle Scholar
• Moghissi K, Dixon K, Gibbins S. Does PDT have potential in the treatment of COVID-19 patients? Photodiagnosis Photodyn Ther. 2020;31(101889):1–2. doi:10.1016/j.pdpdt.2020.101889
   Google Scholar
• Geralde MC, Leite IS, Inada NM, et al. Pneumonia treatment by photodynamic therapy with extracorporeal illumination - an experimental model. Physiol Rep. 2017;5(5):e13190. doi:10.14814/phy2.13190
   PubMedGoogle Scholar
• Kassab G, Geralde MC, Inada NM, Achiles AE, Guerra VG, Bagnato VS. Nebulization as a tool for photosensitizer delivery to the respiratory tract. J Biophotonics. 2019;12(4):e201800189. doi:10.1002/jbio.201800189
   PubMed Web of Science ®Google Scholar
• Schikora D, Hepburn J, Plavin SR. Reduction of the viral load by non-invasive photodynamic therapy in early stages of COVID-19 infection. Am J Virol Dis. 2020;2(1):01–05.
   Google Scholar
• Jin C, Yu B, Zhang J. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for the COVID-19 outbreak. Res Square. 2020;1–15. doi:10.21203/rs.3.rs-17718/v1
   Google Scholar
• Keil SD, Bowen R, Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion. 2016;56(12):2948–2952. doi:10.1111/trf.13860
   PubMed Web of Science ®Google Scholar
• Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2014;44(6):877. doi:10.1111/j.1537-2995.2004.03355.x
   Google Scholar
• Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev. 2002;16(1):61–66. doi:10.1053/tmrv.2002.29405
   PubMed Web of Science ®Google Scholar
• Bachmann B, Knüver-Hopf J, Lambrecht B, et al. Target structures for HIV-1 inactivation by methylene blue and light. J Med Virol. 1995;47(2):172–178. doi:10.1002/jmv.1890470211
   PubMed Web of Science ®Google Scholar
• Bumah VV, Masson-Meyers DS, Enwemeka CS. Pulsed 450 nm blue light suppresses MRSA and propionibacterium acnes in planktonic cultures and bacterial biofilms. J Photochem Photobiol B. 2020;202:111702. doi:10.1016/j.jphotobiol.2019.111702
   PubMed Web of Science ®Google Scholar
• Masson-Meyers DS, Bumah VV, Castel C, et al. Pulsed 450 nm blue light significantly inactivates Propionibacterium acnes more than continuous wave blue light. J Photochem Photobiol B. 2020;202:111719. doi:10.1016/j.jphotobiol.2019.111719
   PubMed Web of Science ®Google Scholar
• Hanna R, Dalvi S, Sălăgean T, et al. Phototherapy as a rational antioxidant treatment modality in COVID-19 management; new concept and strategic approach: critical review. Antioxidants. 2020;9(875):1–23. doi:10.3390/antiox9090875
   Google Scholar
• Photodynamic therapy for the treatment of COVID-19. Available from: https://clinicaltrials.gov/show/NCT04416113. Accessed October 20, 2020.
   Google Scholar
• Photobiomodulation therapy combined with static magnetic field in patients with COVID-19. Available from: https://clinicalTrials.govshow/NCT04386694. Accessed October 20, 2020.
   Google Scholar
• Lung treatment of lung inflammation in COVID-19. Available from: https://clinicalTrials.govshow/NCT04524715. Accessed October 20, 2020.
   Google Scholar
• Photobiomodulation laser therapy for COVID-19 positive patients with pulmonary disease. Available from: https://clinicalTrials.govshow/NCT04391712. Accessed October 20, 2020.
   Google Scholar